- Home
- ELVN vs CDTX Comparison
ELVN vs CDTX Comparison
Compare ELVN & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- CDTX
- Stock Information
- Founded
- ELVN 2016
- CDTX 2012
- Country
- ELVN United States
- CDTX United States
- Employees
- ELVN N/A
- CDTX N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ELVN Health Care
- CDTX Health Care
- Exchange
- ELVN Nasdaq
- CDTX Nasdaq
- Market Cap
- ELVN 1.2B
- CDTX 980.1M
- IPO Year
- ELVN 2020
- CDTX 2015
- Fundamental
- Price
- ELVN $19.32
- CDTX $61.79
- Analyst Decision
- ELVN Strong Buy
- CDTX Strong Buy
- Analyst Count
- ELVN 5
- CDTX 11
- Target Price
- ELVN $41.20
- CDTX $52.11
- AVG Volume (30 Days)
- ELVN 410.5K
- CDTX 700.8K
- Earning Date
- ELVN 08-12-2025
- CDTX 08-07-2025
- Dividend Yield
- ELVN N/A
- CDTX N/A
- EPS Growth
- ELVN N/A
- CDTX N/A
- EPS
- ELVN N/A
- CDTX N/A
- Revenue
- ELVN N/A
- CDTX $302,000.00
- Revenue This Year
- ELVN N/A
- CDTX N/A
- Revenue Next Year
- ELVN N/A
- CDTX N/A
- P/E Ratio
- ELVN N/A
- CDTX N/A
- Revenue Growth
- ELVN N/A
- CDTX N/A
- 52 Week Low
- ELVN $13.30
- CDTX $10.14
- 52 Week High
- ELVN $30.03
- CDTX $66.95
- Technical
- Relative Strength Index (RSI)
- ELVN 40.65
- CDTX 68.87
- Support Level
- ELVN $21.25
- CDTX $60.71
- Resistance Level
- ELVN $22.83
- CDTX $66.95
- Average True Range (ATR)
- ELVN 1.42
- CDTX 4.29
- MACD
- ELVN -0.35
- CDTX -0.32
- Stochastic Oscillator
- ELVN 5.60
- CDTX 72.26
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.